Drug-induced thrombotic microangiopathy: Incidence, prevention and management

Drug Safety

Volumn 24, Issue 7, 2001, Pages 491-501

  Pisoni, R ^a,b   Ruggenenti, P ^a,c   Remuzzi, G ^a,c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLOPIDOGREL; CYCLOSPORIN; INTERFERON; MITOMYCIN; OKT 3; QUININE; TACROLIMUS; TICLOPIDINE;

ARTERIAL PRESSURE; BONE MARROW TRANSPLANTATION; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; ESCHERICHIA COLI; HUMAN; IMMUNOPATHOLOGY; KIDNEY FUNCTION; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SHIGELLA DYSENTERIAE; SHIGELLOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034948863     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200124070-00002     Document Type: Review

References (113)

1. Thrombotic microangiopathies
2. The hemolytic uremic syndrome
3. The pivotal role of the endothelial cell in the pathogenesis of HUS
4. The pathophysiology of the hemolytic uremic syndrome
5. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli 0157: H7 infection
6. Interleukin-8 and polymorphonuclear leukocyte activation in hemolytic uremic syndrome of childhood
7. Neutrophil-mediated endothelial injury in hemolytic uremic syndrome
8. Pathologic effects of plasma in patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells
9. Immunologic and other factors in thrombotic thrombocytopenic purpura
10. A western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies
11. Lyric anti-endothelial cell antibodies in hemolytic-uremic syndrome
12. Pathogenesis of thrombotic thrombocytopenic purpura
13. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus
14. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients
15. Verotoxin-2 induces subendothelial leukocyte transmigration via upregulation of MCP-1 and IL-8
16. Biologic consequences of complement activation
17. Cell biology of von Willebrand factor
18. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura
19. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
20. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura, and the hemolytic-uremic syndrome
21. Abnormalities of factor VIII related protein multimers in the haemolytic uraemic syndrome
22. Alpha1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura
23. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation
24. Moschcowitz, multimers, and metalloprotease
25. Von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers
26. New families with von Willebrand disease type 2M (Vicenza)
27. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families
28. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma
29. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
30. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma
31. Hemolytic uremic syndrome in families
32. The hemolytic uremic syndrome
33. Hereditary thrombotic thrombocytopenic purpura: Microangiopathic hemolytic anemia, thrombocytopenia, and renal insufficiency occurring in consecutive generations
34. Hemolytic-uremic syndrome in adult sisters
35. Hemolytic uremic syndrome in three adult siblings: A familial study and evolution
36. Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3, B7 haplotype
37. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities
38. Hypocomplementemia due to a genetic deficiency of b1H globulin
39. Familial hemolytic-uremic syndrome and homozygous factor H deficiency
40. Genetic studies into inherited and sporadic hemolytic uremic syndrome
41. Microangiopathic hemolytic anemia in metastatic carcinoma: Report of eight cases
42. Renal toxicity in man treated with mitomycin C
43. Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry
44. Cancer- and chemotherapy-associated thrombotic microangiopathy
45. Mitomycin-induced hemolytic uremic kidneys: An experimental model in rat
46. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma
47. Thrombotic thrombocytopenic purpura. A review
48. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents
49. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome
50. Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy. A case report and review of the literature
51. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange
52. Hemolytic-uremic syndrome due to deoxycoformycin: A report of the second case
53. Chronic glomerular microangiopathy and metastatic carcinoma
54. Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy
55. Microangiopathic hemolytic anemia, thrombocytopenia and renal failure in patients treated for adenocarcinoma
56. Carcinoma associated hemolytic-uremic syndrome: A complication of mitomycin C chemotherapy
57. Hemolytic-uremic syndrome caused by gemcitabine
58. Hemolytic uremic syndrome during therapy with estramustine phosphate for advanced prostatic cancer
59. Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin
60. Mitomycin-C pulmonary toxicity protective measures
61. The treatment of thrombotic thrombocytopenic purpura: Plasma infusion or exchange?
62. Cryopoor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)
63. Treatment of cancer-associated hemolytic-uremic syndrome with staphylococcal protein A immunoperfusion
64. Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients
65. The pathophysiology and management of thrombotic thrombocytopenic purpura
66. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: Current concepts and management
67. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation
68. Renal vascular and thrombotic effects of cyclosporine
69. Thrombotic microangiopathy following bone marrow transplantation
70. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
71. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells
72. Cyclosporine-induced hemolytic uremic syndrome: Factors that obscure its diagnosis
73. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome
74. FK506 as an alternative in cyclosporine-induced hemolytic uremic syndrome in a kidney transplant recipient
75. Hemolytic-uremic syndrome in a renal transplant recipient on FK506 immunosuppression
76. FK506-associated thrombotic microangiopathy
77. Cyclosporine nephropathy
78. Renal transplantation under cyclosporine and FK506 for hemolytic uremic syndrome
79. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome
80. Induction of thromboses within renal grafts by high-dose prophylactic OKT3
81. Procoagulant effect of the OKT3 monoclonal antibody: Involvement of tumor necrosis factor
82. Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia
83. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with alpha-interferon
84. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: Coincidence or true side effect?
85. Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients
86. Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C
87. Thrombotic thrombocytopenic purpura related to ticlopidine
88. Thrombotic thrombocytopenic purpura associated with ticlopidine therapy
89. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
90. Thrombotic thrombocytopenic purpura after stenting and ticlopidine
91. Thrombotic thrombocytopenic purpura associated with ticlopidine use. A report of 3 cases and review of the literature
92. Thrombotic thrombocytopenic purpura associated with clopidogrel
93. Quinine-induced hemolytic uremic syndrome
94. Thrombotic thrombocytopenic purpura and simvastatin
95. Postpartum nephrosclerosis in women taking oral contraceptives
96. Microangiopathic hemolysis and thrombocytopenia related to penicillin drugs
97. Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis
98. Thrombotic thrombocytopenic purpura caused by iodine
99. Thrombotic thrombocytopenic purpura due to rifampicin
100. Microvascular diseases of the kidney
101. Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C
102. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia
103. Potential role for antiphospholipid antibodies in renal thrombotic microangiopathy induced by interferon-alpha
104. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon-alpha 2b
105. Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha
106. Recombinant interferon alpha and hemolytic uremic syndrome: Cause or coincidence?
107. Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia
108. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides
109. Recombinant leukocyte interferon α induces steroid-resistant acute vascular rejection episodes in renal transplant recipients
110. Autoimmunity after alpha-interferon therapy for malignant carotid tumors
111. Acute renal failure during therapy with recombinant human gamma interferon
112. Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases
113. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: Clinical and serological findings in nine patients and review of literature